|
1
|
Yan J, Tan C, Gu F, Jiang J, Xu M, Huang
X, Dai Z, Wang Z, Fan J and Zhou J: Sorafenib delays recurrence and
metastasis after liver transplantation in a rat model of
hepatocellular carcinoma with high expression of phosphorylated
extracellular signal-regulated kinase. Liver Transpl. 19:507–520.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roh YN, Kwon David CH, Song S, Shin M, Kim
Man J, Kim S, Joh JW and Lee SK: The prognosis and treatment
outcomes of patients with recurrent hepatocellular carcinoma after
liver transplantation. Clin Transplant. 28:141–148. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alsina AE: Liver transplantation for
hepatocellular carcinoma. Cancer Control. 17:83–86. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baccarani U, Isola M, Adani GL, Benzoni E,
Avellini C, Lorenzin D, Bresadola F, Uzzau A, Risaliti A, Beltrami
AP, et al: Superiority of transplantation versus resection for the
treatment of small hepatocellular carcinoma. Transpl Int.
21:247–254. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim HR, Cheon SH, Rha SY, Lee S, Han KH,
Chon CY, Lee JD, Sung JS and Chung HC: Treatment of recurrent
hepatocellular carcinoma after liver transplantation. Asia Pac J
Clin Oncol. 7:258–269. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee KK, Kim DG, Moon IS, Lee MD and Park
JH: Liver transplantation versus liver resection for the treatment
of hepatocellular carcinoma. J Surg Oncol. 101:47–53. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shah SA, Cleary SP, Wei AC, Yang I, Taylor
BR, Hemming AW, Langer B, Grant DR, Greig PD and Gallinger S:
Recurrence after liver resection for hepatocellular carcinoma: Risk
factors, treatment, and outcomes. Surgery. 141:330–339. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gomez-Martin C, Bustamante J, Castroagudin
JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A and
Sangro B: Efficacy and safety of sorafenib in combination with
mammalian target of rapamycin inhibitors for recurrent
hepatocellular carcinoma after liver transplantation. Liver
Transpl. 18:45–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tan WF, Qiu ZQ, Yu Y, Ran RZ, Yi B, Lau
WY, Liu C, Qiu YH, Feng FL, Wang JH, et al: Sorafenib extends the
survival time of patients with multiple recurrences of
hepatocellular carcinoma after liver transplantation. Acta
Pharmacol Sin. 31:1643–1648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Staufer K, Fischer L, Seegers B,
Vettorazzi E, Nashan B and Sterneck M: High toxicity of sorafenib
for recurrent hepatocellular carcinoma after liver transplantation.
Transpl Int. 25:1158–1164. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zavaglia C, Airoldi A, Mancuso A, Vangeli
M, Viganò R, Cordone G, Gentiluomo M and Belli LS: Adverse events
affect sorafenib efficacy in patients with recurrent hepatocellular
carcinoma after liver transplantation: Experience at a single
center and review of the literature. Eur J Gastroenterol Hepatol.
25:180–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mueller AR, Platz KP, Bechstein WO,
Schattenfroh N, Stoltenburg-Didinger G, Blumhardt G, Christe W and
Neuhaus P: Neurotoxicity after orthotopic liver transplantation. A
comparison between cyclosporine and FK506. Transplantation.
58:155–170. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Geissler EK, Schnitzbauer AA, Zülke C,
Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten
TM, et al: Sirolimus use in liver transplant recipients with
hepatocellular carcinoma: A randomized, multicenter, Open-Label
phase 3 trial. Transplantation. 100:116–125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alessiani M, Cillo U, Fung JJ, Irish W,
Abu-Elmagd K, Jain A, Takaya S, Van Thiel D and Starzl TE: Adverse
effects of FK 506 overdosage after liver transplantation.
Transplant Proc. 25:628–634. 1993.PubMed/NCBI
|
|
15
|
Taniai N, Akimaru K, Ishikawa Y, Kanada T,
Kakinuma D, Mizuguchi Y, Mamada Y, Yoshida H and Tajiri T:
Hepatotoxicity caused by both tacrolimus and cyclosporine after
living donor liver transplantation. J Nippon Med Sch. 75:187–191.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang ZH, Li LX, Li P, Lv SC, Pan B and He
Q: Sirolimus in liver transplant recipients with hepatocellular
carcinoma: An updated meta-analysis. J Invest Surg. 1–10. 2018.
View Article : Google Scholar
|
|
17
|
Toso C, Merani S, Bigam DL, Shapiro AM and
Kneteman NM: Sirolimus-based immunosuppression is associated with
increased survival after liver transplantation for hepatocellular
carcinoma. Hepatology. 51:1237–1243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guba M, von Breitenbuch P, Steinbauer M,
Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S,
Anthuber M, et al: Rapamycin inhibits primary and metastatic tumor
growth by antiangiogenesis: Involvement of vascular endothelial
growth factor. Nat Med. 8:128–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shao H, Gao C, Tang H, Zhang H, Roberts
LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, et al: Dual
targeting of mTORC1/C2 complexes enhances histone deacetylase
inhibitor-mediated anti-tumor efficacy in primary HCC cancer in
vitro and in vivo. J Hepatol. 56:176–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li C, Wu X, Zhang H, Yang G, Hao M, Sheng
S, Sun Y, Long J, Hu C, Sun X, et al: A Huaier polysaccharide
inhibits hepatocellular carcinoma growth and metastasis. Tumour
Biol. 36:1739–1745. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X, Zhang N, Huo Q and Yang Q:
Anti-angiogenic and antitumor activities of Huaier aqueous extract.
Oncol Rep. 28:1167–1175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang N, Kong X, Yan S, Yuan C and Yang Q:
Huaier aqueous extract inhibits proliferation of breast cancer
cells by inducing apoptosis. Cancer Sci. 101:2375–2383. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garaci E, Pica F, Serafino A, Balestrieri
E, Matteucci C, Moroni G, Sorrentino R, Zonfrillo M, Pierimarchi P
and Sinibaldi-Vallebona P: Thymosin α1 and cancer: Action on immune
effector and tumor target cells. Ann N Y Acad Sci. 1269:26–33.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Serafino A, Pierimarchi P, Pica F,
Andreola F, Gaziano R, Moroni N, Zonfrillo M, Sinibaldi-Vallebona P
and Garaci E: Thymosin α1 as a stimulatory agent of innate
cell-mediated immune response. Ann N Y Acad Sci. 1270:13–20. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alsina AE, Nakshabandi A, Makris AM and
Torres EA: Liver transplantation for hepatocellular carcinoma in
Puerto Ricans: Underutilization of a curative therapy. P R Health
Sci J. 33:170–176. 2014.PubMed/NCBI
|
|
26
|
Mathai AM, Kapadia MJ, Alexander J,
Kernochan LE, Swanson PE and Yeh MM: Role of Foxp3-positive
tumor-infiltrating lymphocytes in the histologic features and
clinical outcomes of hepatocellular carcinoma. Am J Surg Pathol.
36:980–986. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen L, Lu P, Lu Z and Dechun L:
Anticancer effect of PS-T on the experimental hepatocellular
carcinoma. Chin German J Clin Oncol. 3:55–59. 2004. View Article : Google Scholar
|
|
28
|
Wang CY, Bai XY and Wang CH: Traditional
Chinese medicine: A treasured natural resource of anticancer drug
research and development. Am J Chin Med. 42:543–559. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu Z, Yang A, Fan H, Wang Y, Zhao Y, Zha
X, Zhang H and Tu P: Huaier aqueous extract sensitizes cells to
rapamycin and cisplatin through activating mTOR signaling. J
Ethnopharmacol. 186:143–150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun Y, Sun T, Wang F, Zhang J, Li C, Chen
X, Li Q and Sun S: A polysaccharide from the fungi of Huaier
exhibits anti-tumor potential and immunomodulatory effects.
Carbohydr Polym. 92:577–582. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou L, Su XJ, Pan LC, Du GS, Zheng YG,
Xiao L, Kong XR, Gao Y, Zhu ZD, Song JY, et al: Long-Time survival
experience of sirolimus in combination with thymosin alpha −1 and
huaier granule for prevention tumor-recurrence in liver
transplantation recipient of advanced intrahepatic
cholangiocarcinoma: A case report. Ausin J Cancer Clin.
1:10752017.
|
|
32
|
Lei JY, Yan LN, Zhu JQ and Wang WT:
Hepatocellular carcinoma patients may benefit from postoperative
huaier aqueous extract after liver transplantation. Transplant
Proc. 47:2920–2924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou L, Du GS, Pan LC, Zheng YG, Liu ZJ,
Shi HD, Yang SZ, Shi XJ, Xuan M, Feng LK and Zhu ZD: Sirolimus
treatment for cirrhosis or hepatocellular carcinoma patients
accompanied by psoriasis after liver transplantation: A single
center experience. Oncol Lett. 14:7817–7824. 2017.PubMed/NCBI
|
|
34
|
Chen X, Du Y and Huang Z: CD4+CD25+ Treg
derived from hepatocellular carcinoma mice inhibits tumor immunity.
Immunol Lett. 148:83–89. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee WC, Wu TJ, Chou HS, Yu MC, Hsu PY, Hsu
HY and Wang CC: The impact of CD4+CD25+ T cells in the tumor
microenvironment of hepatocellular carcinoma. Surgery. 151:213–222.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li F, Guo Z, Lizée G, Yu H, Wang H and Si
T: Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells
in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B
hepatocellular carcinoma patients. Clin Chem Lab Med. 52:1357–1365.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ozgur HH, Ercetin AP, Eliyatkin N, Seren
A, Kupelioglu A, Ortac R, Diniz G and Aktas S: Regulatory T cells
and their prognostic value in hepatopancreatobiliary tumours.
Hepatogastroenterology. 61:1847–1851. 2014.PubMed/NCBI
|
|
38
|
Romani L, Bistoni F, Montagnoli C, Gaziano
R, Bozza S, Bonifazi P, Zelante T, Moretti S, Rasi G, Garaci E and
Puccetti P: Thymosin alpha1: An endogenous regulator of
inflammation, immunity, and tolerance. Ann N Y Acad Sci.
1112:326–338. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ji SM, Li LS, Sun QQ, Chen JS, Sha GZ and
Liu ZH: Immunoregulation of thymosin alpha 1 treatment of
cytomegalovirus infection accompanied with acute respiratory
distress syndrome after renal transplantation. Transplant Proc.
39:115–119. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wolf E, Milazzo S, Boehm K, Zwahlen M and
Horneber M: Thymic peptides for treatment of cancer patients.
Cochrane Database Syst Rev: CD003993. 2011. View Article : Google Scholar
|
|
41
|
Joosten SA, van Meijgaarden KE, Savage ND,
de Boer T, Triebel F, van der Wal A, de Heer E, Klein MR, Geluk A
and Ottenhoff TH: Identification of a human CD8+ regulatory T cell
subset that mediates suppression through the chemokine CC chemokine
ligand 4. Proc Natl Acad Sci USA. 104:8029–8034. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang Y, Liao H, Zhang Y, Yuan R, Wang F,
Gao Y, Wang P and Du Z: Prognostic value of Tumor-Infiltrating
FoxP3+ T cells in gastrointestinal cancers: A meta analysis. PLoS
One. 9:e943762014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pons JA, Revillanuin B, Ramírez P,
Baroja-Mazo A and Parrilla P: Development of immune tolerance in
liver transplantation. Gastroenterol Hepatol. 34:155–169. 2011.(In
Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Karczewski M, Karczewski J, Kostrzewa A,
Wiktorowicz K and Glyda M: The role of foxp3+ regulatory T cells in
kidney transplantation. Transpl Proc. 41:1527–1529. 2009.
View Article : Google Scholar
|
|
45
|
Shang B and Liu Y, Jiang SJ and Liu Y:
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in
cancers: A systematic review and meta-analysis. Sci Rep.
5:151792015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Casares N, Arribillaga L, Sarobe P, Dotor
J, de Cerio Lopez-Diaz A, Melero I, Prieto J, Borrás-Cuesta F and
Lasarte JJ: CD4+/CD25+ regulatory cells inhibit activation of
tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic
activity, as well as long-lasting tumor immunity elicited by
peptide vaccination. J Immunol. 171:5931–5939. 2003. View Article : Google Scholar : PubMed/NCBI
|
